ELAN 351 Extension - A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with AD who Participated in Study ELN115727-301 or ELN115727-302

Detalles del proyecto

EstadoFinalizado
Fecha de inicio/Fecha fin5/13/10 → 4/30/14

Financiación

  • Janssen Alzheimer Immunotherapy Research and Development LLC: 206.766,00 US$